Generic Name and Formulations:
Capsaicin 8% (179mg); patch.
Indications for QUTENZA:
Management of neuropathic pain associated with post-herpetic neuralgia.
Identify treatment area and mark the skin; may cut patches to match size and shape of area. Pretreat with topical anesthetic to reduce discomfort, once anesthetized, remove anesthetic and wash the treatment area. Apply to dry, intact skin within 2 hours of opening patch. Apply patch (up to 4 may be used) for 60 minutes, repeat every 3 months or as warranted by the return of pain (not more frequently than every 3 months). May use a dressing to ensure patch remains in contact with treatment area. After removal of patch, apply Cleansing Gel to area and leave on for at least one minute. Remove Cleansing Gel with dry wipe; wash and dry the area. Treat acute pain during and following the procedure with local cooling and/or analgesics. Use nitrile gloves when handling patch and cleaning capsaicin residue from skin. Immediately dispose of patches.
<18yrs: not recommended.
Should only be administered by a physician or healthcare professional. Aerosolization of capsaicin may occur with rapid removal of patches, remove patches slowly by rolling the adhesive side inward. Avoid exposure to eyes, mucous membranes. Evaluate for recent history of cardio- and cerebrovascular disease. Monitor BP periodically during treatment. Pregnancy (Cat.B). Nursing mothers; do not breastfeed after treatment on the day of treatment.
TRPV1 channel agonist.
Application site reactions (eg, erythema, pain, pruritus, papules); increased blood pressure.
Patch—1, 2 (both with 50g tube of Cleansing Gel)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma